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Articles
Resistance to thyroid hormone caused by a mutation in 
thyroid hormone receptor (TR)α1 and TRα2: clinical, 
biochemical, and genetic analyses of three related patients
Carla Moran*, Maura Agostini*, W Edward Visser, Erik Schoenmakers, Nadia Schoenmakers, Amaka C Oﬃ  ah, Ken Poole, Odelia Rajanayagam, 
Greta Lyons, David Halsall, Mark Gurnell, Dionisios Chrysis, Alexandra Efthymiadou, Charles Buchanan, Simon Aylwin, Krishna K Chatterjee
Summary
Background The thyroid hormone receptor α gene (THRA) transcript is alternatively spliced to generate either thyroid 
hormone receptor (TR)α1 or a non-hormone-binding variant protein, TRα2, the function of which is unknown. Here, 
we describe the ﬁ rst patients identiﬁ ed with a mutation in THRA that aﬀ ects both TRα1 and TRα2, and compare 
them with patients who have resistance to thyroid hormone owing to a mutation aﬀ ecting only TRα1, to delineate the 
relative roles of TRα1 and TRα2.
Methods We did clinical, biochemical, and genetic analyses of an index case and her two sons. We assessed physical 
and radiological features, thyroid function, physiological and biochemical markers of thyroid hormone action, and 
THRA sequence.
Findings The patients presented in childhood with growth failure, developmental delay, and constipation, which 
improved after treatment with thyroxine, despite normal concentrations of circulating thyroid hormones. They had 
similar clinical (macrocephaly, broad faces, skin tags, motor dyspraxia, slow speech), biochemical (subnormal ratio of 
free thyroxine:free tri-iodothyronine [T3], low concentration of total reverse T3, high concentration of creatine kinase, 
mild anaemia), and radiological (thickened calvarium) features to patients with TRα1-mediated resistance to thyroid 
hormone, although our patients had a heterozygous mis-sense mutation (Ala263Val) in both TRα1 and TRα2 proteins. 
The Ala263Val mutant TRα1 inhibited the transcriptional function of normal receptor in a dominant-negative fashion. 
By contrast, function of Ala263Val mutant TRα2 matched its normal counterpart. In vitro, high concentrations of T3 
restored transcriptional activity of Ala263Val mutant TRα1, and reversed the dominant-negative inhibition of its 
normal counterpart. High concentrations of T3 restored expression of thyroid hormone-responsive target genes in 
patient-derived blood cells.
Interpretation TRα1 seems to be the principal functional product of the THRA gene. Thyroxine treatment alleviates hormone 
resistance in patients with mutations aﬀ ecting this gene, possibly ameliorating the phenotype. These ﬁ ndings will help the 
diagnosis and treatment of other patients with resistance to thyroid hormone resulting from mutations in THRA.
Funding Wellcome Trust, NIHR Cambridge Biomedical Research Centre, Marie Curie Actions, Foundation for 
Development of Internal Medicine in Europe.
Introduction
The physiological actions of thyroid hormones are 
mediated by nuclear receptors (thyroid receptor [TR]α and 
TRβ) encoded by separate genes (THRA and THRB), 
which regulate gene expression in target tissues. TRs bind 
to DNA usually as a heterodimer with retinoid X receptor. 
When not bound to thyroid hormone, TR binds to the 
promoters of thyroid hormone-target genes—within gene 
promoter regions known as thyroid response elements—
in complex with multiprotein corepressor complexes, 
inhibiting gene transcription. When thyroid hormone 
binds to a TR, a conformational change leads to dissociation 
of corepressor proteins and coactivator proteins can 
associate with the receptor, leading to transcriptional 
activation of target genes.1
Alternative splicing of the THRA transcript generates 
two subtypes of TRα with identical aminoterminal and 
DNA-binding domains, but diﬀ erent carboxyterminal 
regions. Because of this diﬀ erence, TRα1 binds thyroid 
hormone. By contrast, TRα2 does not bind thyroid 
hormone but does bind DNA. TRα1 is most highly 
expressed in myocardium, skeletal muscle, the 
gastrointestinal tract, and the CNS; some forms of TRα1 
that are truncated at the aminoterminus are expressed in 
mitochondria, aﬀ ecting its function.2,3 TRα2 is widely 
expressed, but its function is not understood.3
The incidence of resistance to thyroid hormone 
mediated by defective TRβ is roughly 1 in 40 000 people, 
and several hundred heterozygous mutations in THRB 
gene (most within three hotspots in the thyroid hormone-
binding domain) have been identiﬁ ed in people with this 
disorder.4 Consistent with the dominant inheritance 
pattern observed for this disorder, mutant TRβ proteins 
inhibit the function of their normal counterparts in a 
dominant-negative manner—probably caused by 
constitutive repression of target gene transcription 
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resulting from failure of the corepressor complex to 
dissociate from mutant TRβ.5 Based on the homology 
(95%) of their thyroid hormone-binding domains, 
analogous mutations in human TRα had been predicted,6 
but only three diﬀ erent frameshift-stop or premature-
stop mutations within a TRα1-speciﬁ c, carboxyterminal-
encoding exon have been described.7–10 However, mouse 
models with TRα1 mutations in other regions of the 
gene11–14 have been generated and have varying 
phenotypes, suggesting that molecular and clinical 
heterogeneity of the human disorder might be shown.
Here, we describe the ﬁ rst family with a THRA defect 
resulting in mutation of both TRα1 and TRα2.
Methods
The index patient (patient 1, a 60-year-old woman) had 
features suggesting hypothyroidism at age 2 years 
(increased bodyweight, poor linear growth, constipation, 
and a large, prominent tongue), but her thyroid hormone 
concentrations were within the normal ranges. 
Nevertheless, she was treated with thyroxine—which 
improved her growth and constipation—and has continued 
to take the drug since.
Her eldest son (patient 2, age 30 years) was delivered 
by caesarean section because of macrocephaly. At age 
6 weeks, he had to switch from breastfeeding to bottle-
feeding to correct poor nutritional intake. His 
subsequent growth and developmental milestones 
(using a ball, speech) were delayed and—because his 
mother had had similar symptoms—he started 
thyroxine treatment at age 3 years, despite his thyroid 
hormone concentrations being within the normal 
ranges. Although his growth and development 
improved, his motor coordination remained poor—
causing imbalance, clumsiness, and poor handwriting—
and he attended a specialist school for children with 
Figure 1: Phenotypic features
(A) Patients 1, 2, and 3. (B) Head circumferences by height and sex, divided into centiles (adapted with permission from Bushby and colleagues15). (C) Skull radiograph of 
patient 1. (D) Free thyroxine:free tri-iodothyronine ratios, compared with sex-matched healthy people of similar age (women 35–64 years, men 20–40 years).15 
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motor dyspraxia. He continued to take thyroxine 
throughout childhood and adulthood, except for an 
interval (26–29 years), during which time he noted 
constipation, weight gain, lethargy, and low mood.
A second son (patient 3, age 26 years) was delivered by 
elective caesarean section. He had a large tongue and 
similar facial appearance to patient 2, and had 
drowsiness and delayed linear growth, speech and motor 
development, which improved after treatment with 
thyroxine from age 3 years. He also has signiﬁ cant 
motor incoordination, for which he needed specialist 
schooling. A third son is unaﬀ ected, with normal growth 
and development.
We took serial measurements of biochemical 
characteristics (thyroid function, sex-hormone-binding 
globulin, creatine kinase, lipids, bone turnover 
markers) and physiological characteristics (sleeping 
heart rate, resting energy expenditure) when patients 
were and were not taking thyroxine, as described 
previously,7,10 and compared these data with reference 
measurements from age and sex-matched people from 
a healthy volunteer cohort recruited by our clinical 
research facility. We did molecular genetic analysis of 
THRA and functional characterisation of mutant TRα1 
and TRα2 (appendix).7,10 We compared diﬀ erences in 
normal and mutant receptor function with a two-tailed 
t-test using Excel (version 14.3.9). We did structural 
modelling of mutant TRα1, TRα2 and TRβ proteins 
using MacPyMOL Molecular Graphics System 
(version 1.5.0.4). All investigations were part of an 
ethically approved protocol or were clinically indicated. 
All patients gave informed written consent.
Role of the funding source
The funders had no role in study design, collection, 
analysis or interpretation of the data, writing the 
report, or the decision to submit the report for 
publication.
See Online for appendix
Patient 1 
(woman, age 61 years)
Patient 2 
(man, age 30 years)
Patient 3 
(man, age 26 years)
Reference values
Thyroxine dose (μg per day) 0 75 0 150 0 150 ··
Weight (kg) 70·3 69·6 84·0 84·4 104·3 106·0 ··
BMI (kg/m²) 28·52 28·24 24·28 24·40 33·29 33·83 ··
Sleeping heart rate (beats per min) 58 62 53 54 55 51 40–68*
Resting energy expenditure (Z score) –1·93 –1·82 –3·06 –1·75 –3·35 –0·30 ··
TSH (mU/L) 4·60 0·12 4·80 <0·03 3·2 0·54 0·35–5·50
Free thyroxine (pmol/L) 9·4 13·9 10·5 17·0 9·7 11·0 10·0–19·8
Total thyroxine (nmol/L) 60·0 96·1 76·6 130 66·3 83·6 69–141
Free T3 (pmol/L) 4·4 6·3 6·4 8·7 6·8 8 3·5–6·5
Total T3(nmol/L) 1·3 1·6 1·7 2·3 2·1 2·4 0·9–2·8
Reverse T3 (ng/L) <50 70 50 120 <50 <50 80–250
Thyroglobulin (μg/L) 14·0 1·1 69·7 2·6 23·6 3·2 3·0–40·0
Total creatine kinase (U/L)† 364 178 385 242 184 295 26–192
SHBG (nmol/L) 45·5 45·7 28·2 32·8 14 13·6 Men 10–57, women 18–144
Total cholesterol (mmol/L) 7·9 7·2 5·2 4·3 4·2 4·0 <5 for a healthy adult in the UK
LDL cholesterol (mmol/L) 5·06 4·72 3·20 2·53 2·34 2·09 <3 for a healthy adult in the UK
IGF-1 (nmol/L) 9·9 11·4 24·3 26·9 32·9 31·7 Women 11·8–28·6, men 16·3–39·3
Markers of bone turnover‡
Formation
Bone-speciﬁ c alkaline phosphatase (ng/mL) 12·6 14·8 17·4 15·4 10·7 11·8 Women (post-menopausal) 3·8–22·6, men 5·7–32·9
Osteocalcin (ng/mL) 9·7 10·7 13·0 16·8 12·7 12·9 Women (post-menopausal) 15–46, men (age 18–30 years) 24–70
P1NP (ng/mL) 26·3 27·3 55·2 56·3 52·8 46·6 Women (post-menopausal) 20·25–76·31
Resorption
CTx (ng/mL) 0·389 0·339 0·700 0·839 0·585 0·525 Women (post-menopausal) 0·104–1·008, men (age 30–50 years) 
0·096–0·584
NTx:Cr 24·5 30·8 25·3 24·7 19·5 28·2 Men 21–83
Red blood cell mass (1012/L) 3·74 3·70 4·23 4·27 4·17 4·16 Women 3·8–5·3 × 1012/L, men 4·20–5·80 × 1012/L
Mean corpuscular volume (fL) 94·8 95·5 92·5 92·6 88·0 88·2 80–100
Haemoglobin concentration (g/L) 120 120 129 129 125 124 Women 115–160, men 130–170
CK-MM=skeletal muscle isoenzyme of creatine kinase. P1NP=procollagen type 1 N-propeptide. CTx=C-terminal cross-linking telopeptide of type 1 collagen. NTx:Cr=N-terminal cross-linking telopeptide of type 1 
collagen:creatinine ratio. SHBG=sex hormone-binding globulin. T3=tri-iodothyronine. TSH=thyroid-stimulating hormone. *From 148 healthy volunteers. †Only CK-MM isoenzyme detected. ‡When taking 
chronic thyroxine treatment. 
Table: Biochemical and metabolic characteristics of patients when or when not receiving thyroxine
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Results
All patients were taking thyroxine when referred, and 
were assessed both while taking treatment and 6 weeks 
after discontinuation. The patients had a broad face, 
ﬂ attened nasal bridges, and prominent tongue (ﬁ gure 1A). 
Patient 1’s stature was normal (height 1·57 m, mid-
parental height 1·69 m) and proportionate (sitting height 
83·8 cm [Z score –1·3] subischial leg length 0·73 m 
[Z score –0·3], but head circumference was large 
(57·5 cm, >97th centile, ﬁ gure 1B). Patient 2 was 
proportionately tall (height 1·86, mid-parental height 
1·78 m, sitting height 0·97 m [Z score +1·1], subischial 
leg length 0·89 m [Z score +1·6]), with a substantially 
large head circumference (64·8 cm, >97th centile, 
ﬁ gure 1B). Patient 3 was also proportionate (height 1·77 m 
mid-parental height 1·78, sitting height 0·95 m [Z score 
+0·3], subischial leg length 0·83 m [Z score +0·15]), but 
macrocephalic (head circumference 62 cm, >97th centile, 
ﬁ gure 1B). Patients 2 and 3 have numerous skin tags and 
moles and their speech is dysarthric. None of the patients 
have had their IQ properly tested, but that of patient 3 
was low average (88) at school and all have achieved an A 
level educational qualiﬁ cation (or equivalent).
All patients had a thickened skull vault (cranial 
hyperostosis; ﬁ gure 1C). Patient 1’s bone mineral density 
T scores were slightly low at the hip (by dual-energy x-ray 
absorptiometry –1·0; by quantitative CT –1·7) and at the 
femoral neck (by quantitative CT –0·5), but normal at 
lumbar spine (+1·9). By contrast, patients 2 and 3 both had 
high bone mineral density T scores at these sites (by dual-
energy x-ray absorptiometry patient 2: hip +0·8, lumbar 
spine +1·9; patient 3: hip +1·4, lumbar spine +1·9) and 
quantitative CT (patient 2: total hip +1·52 [94th centile for 
age], femoral neck +1·7 [96th centile for age]; patient 3: 
total hip +1·9 [97th centile for age], femoral neck +2·8 
[99th centile for age]).
When not taking thyroxine, all patients had normal 
concentrations of thyroid-stimulating hormone (TSH). 
Patient 1 and patient 3 had marginally low and patient 2 
had low-to-normal free thyroxine concentrations; patient 1 
Figure 2: Functional properties and molecular modelling of Ala263Val TRα1
(A) Results of transfection assay for T3-dependent activation in JEG-3 cells transfected with empty, wild-type, or Ala263Val TRα1 expression vectors together with a thyroid hormone-responsive 
reporter gene; the inset shows an electrophoretic mobility shift assay with comparable interaction of unliganded or hormone-bound normal TRα1 and RXR, and Ala263Val mutant TRα1 and RXR 
heterodimers with a direct repeat thyroid response element from the malic enzyme gene. (B) We tested dominant-negative inhibition in cells cotransfected with reporter gene and equal combinations 
of expression vectors. (C) Quantitative real-time PCR (internal control: 36B4, acidic ribosomal phosphoprotein) showing expression of KLF9 in peripheral blood mononuclear cells from the patients 
(Ala263Val) or control individuals with changing T3 concentrations. (D) Crystallographic modelling of the TRα1 ligand binding domain bound to tri-iodothyronine (blue). (E) Structures of TRα1, TRα2 
and TRβ proteins. *p<0·05. †p<0·01. ‡p<0·001. DBD=DNA-binding domain. T3=tri-iodothyronine. RXR=retinoid X receptor. RL=reticulocyte lysate.
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and patient 2 had normal and patient 3 had slightly high 
free tri-iodothyronine (T3) concentrations (table). However, 
all patients had a low ratio of thyroxine:T3 (ﬁ gure 1D), 
with subnormal concentrations of reverse T3 (table). Their 
resting energy expenditure was greatly reduced compared 
with healthy controls, with high concentration of skeletal 
muscle creatine kinase and mild, normocytic, anaemia 
(table). Sequencing of THRA showed that the patients 
were heterozygous for a nucleotide substitution (GCG to 
GTG), corresponding to an alanine to valine change at 
codon 263 in the sequence common to both TRα1 and 
TRα2; the mutation segregates with abnormal phenotype 
and thyroid biochemistry, being present in the three 
patients but absent in unaﬀ ected family members 
(sibling, father; appendix) and from normal genome 
databases (dBSNP, 1000 Genomes, NHLBI exome 
variant server).
Restriction fragment length polymorphism analysis and 
direct sequencing of TRα1 and TRα2 cDNAs derived from 
primary blood mononuclear cells from patient 1 conﬁ rmed 
that Ala263Val mutant TRα1 and TRα2 mRNAs are 
coexpressed together with normal variant transcripts in 
vivo (appendix). Lack of antibodies that reliably distinguish 
between TRα1 and TRα2 subtypes, and between normal 
and mutant TRs, precluded testing for expression at the 
protein level.
Figure 3: Functional properties of Ala263Val TRα2
(A) 293 cells transfected with either GFP, GFP-tagged normal TRα2, or Ala263Val mutant TRα2 expression vectors with visualisation of nuclei (blue), plasma membrane (red), and GFP fusion (green), 
and a composite merged image by immunoﬂ uorescence. We tested transcriptional function of wild-type TRα2 and Ala263Val mutant TRα2 proteins in JEG-3 cells cotransfected with reporter gene and 
increasing amounts (5–250 ng) of empty, normal, or Ala263Val TRα2 expression vectors in the absence of tri-iodothyronine (B), or a ﬁ xed amount of empty, TRα1, normal TRα2, and Ala263Val mutant 
TRα2 expression vectors with increasing T3 concentrations (C; inset show magniﬁ ed vector, α2, Ala263Val α2 responses), or a ﬁ xed amount of wild-type TRα1 and increasing ratio (1:1 to 1:50) of TRα2 
expression vectors (D; inset shows western blot of ﬂ ag epitope-tagged TR and control [β actin] proteins). T3=tri-iodothyronine.
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Binding of the Ala263Val mutant TRα1 to radiolabelled 
T3 was greatly reduced compared with normal receptor 
(appendix), consistent with structural modelling, which 
predicted that the Ala263Val substitution would impair T3 
binding to the receptor owing to steric hindrance 
(ﬁ gure 2D). In transfection assays, Ala263Val mutant TRα1 
had little eﬀ ect on transcriptional activation of a thyroid 
hormone-responsive target gene at low concentrations of 
T3 (0·001–10 nM; ﬁ gure 2A), but at higher concentrations 
(100–10 000 nM) mutant receptor function was similar to 
that of normal receptor. Ala263Val mutant TRα1 was able 
to bind to DNA (ﬁ gure 2A) and, when coexpressed with 
wild-type TRα1, it inhibited the transcriptional activity of 
its normal counterpart in a dominant-negative manner 
(ﬁ gure 2B, appendix). High concentrations of T3 (100 nM) 
reversed such inhibition in vitro and also reversed reduced 
expression of a thyroid hormone-responsive target gene 
(KLF9) in patient-derived peripheral blood mononuclear 
cells studied ex vivo (ﬁ gure 2B, C). Consistent with reversal 
of dominant-negative inhibition by mutant TRα1 at high T3 
concentrations, higher (1000 nM) concentrations fully 
dissociated Ala263Val mutant TRα1 from a corepressor 
(NCoR) and recruited a coactivator (TRAP220) in assays 
that measured receptor interactions with cofactors 
(appendix). Ala263Val mutant TRα1 fails to dissociate from 
NCoR or to associate fully with TRAP220 at concentrations 
that would be suﬃ  cient for normal receptor.
In comparison with its normal counterpart, the 
Ala263Val mutant TRα2 had similar cellular localisation, 
similarly negligible transcriptional function in either the 
absence or presence of T3, and similarly weak dominant-
negative activity when overexpressed (ﬁ gure 3).
After thyroxine treatment at a replacement dose 
(1·1–1·8 μg/kg), free thyroxine and free T3 increased in all 
patients, TSH concentrations and circulating thyroglobulin 
concentrations fell. Total reverse T3 concentration rose in 
patients 1 and 2 but was unchanged in patient 3 (table). 
Resting energy expenditure rose in all patients during 
treatment, but remained subnormal, with a smaller 
increase for patient 1, who takes lower doses of thyroxine 
(75 μg vs 150 μg). Concurrently, LDL-cholesterol 
concentrations fell in all patients (table). Creatine kinase 
concentration fell in patient 1 and patient 2, but increased 
in patient 3 (table). Many, but not all, markers of bone 
turnover increased, but sleeping heart rate changed little 
(table). All patients noted that their symptoms improved 
after restarting thyroxine: paraesthesiae suggestive of 
carpal tunnel syndrome resolved in patient 1, while both 
patient 2 and patient 3 reported reduced motor 
incoordination and constipation.
Discussion
The patients had many clinical features that suggest 
hypothyroidism (growth retardation, developmental 
delay, constipation, macrocephaly, large tongue), despite 
normal concentrations of circulating thyroid hormones. 
However, they had a subnormal free thyroxine:free 
T3 ratio, low reverse T3 concentration, high muscle 
creatine kinase concentration, and mild anaemia. The 
clinical and biochemical features of our patients are 
similar to the phenotype of patients with defective TRα1 
alone,7–10 with no added characteristics attributable to any 
change to TRα2 function. Our observations accord with 
the absence of a phenotype linked speciﬁ cally to TRα2 
deﬁ ciency in a knockout mouse line.16 A patient with a 
diﬀ erent, sporadic THRA mutation (asn359tyr) in both 
α1 and α2 subtypes,17 had many dissimilar features (eg, 
clavicular agenesis, humeroradial synostosis, syndactyly, 
chronic diarrhoea, primary hyperparathyroidism), which 
are not present in TRα2 knockout mice,16 and it is not 
clear whether these additional abnormalities are caused 
by the THRA mutation alone.18
The alanine at codon 263 of TRα is highly conserved in 
diﬀ erent species (ﬁ gure 2E). The Ala263Val mutation is 
common to both TRα1 and α2, whereas previously 
described THRA mutations (glu403X, phe397fs406X, 
ala382PfsX7) are unique to TRα1. Three clusters of TRβ 
mutations (at amino acids 426–460, 309–353, and 
234–282) are associated with resistance to thyroid 
hormone β and we have identiﬁ ed a TRβ mutation 
(ala317val) analogous to the Ala263Val mutation in TRα1 
that localises to one of these hotspots (ﬁ gure 2E). The 
dysfunction of ala317val mutant TRβ resembles that of 
Ala263Val mutant TRα1, with severely reduced thyroid 
hormone binding, impaired thyroid hormone-dependent 
transcriptional activation, and dominant-negative activity 
that is reversible at high concentrations of T3 (appendix). 
Structural modelling shows how T3 binding might be 
impaired (appendix). This amino acid change involves a 
residue that has previously been reported mutated to 
threonine in patients with resistance to thyroid 
hormone,19 and is within a recognised mutation cluster 
aﬀ ecting the thyroid hormone-binding domain of TRβ in 
patients with this disorder (ﬁ gure 2E).
The index patient with the ala317val TRβ mutation 
presented at age 4 years, with a thyroglossal cyst, high 
thyroid hormone concentration, and unsuppressed 
thyroid-stimulating hormone. Aﬀ ected family members 
(mother and two siblings) had the same biochemical 
proﬁ le, together with high reverse T3 and thyroglobulin 
concentrations and these biochemical abnormalities 
segregate with heterozygosity for the ala317val mutation 
in TRβ (appendix). Each patient had features of resistance 
to thyroid hormone (proband: failure to thrive and 
increased appetite; sibling 1: frequent upper respiratory 
tract infections, hyperactivity, mild learning diﬃ  culties, 
and increased appetite; sibling 2: failure to thrive) and 
their resting energy expenditure was high (proband: 
142%; sibling 1: 152%; sibling 2: 122%; mother: 127%; 
normal: 95–105% of predicted values). The diﬀ erences 
between patients with the ala317val mutation in TRβ and 
those with the Ala263Val mutation in TRα1 underscores 
the importance of TRβ for mediating negative feedback 
within the hypothalamo-pituitary–thyroid axis and TRα 
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for mediating hormone action in the periphery (muscle, 
myocardium, gastrointestinal tract).
Our ﬁ nding that the Ala263Val substitution inhibits 
binding of T3 through steric hindrance provides a basis 
for the impaired hormone binding and transcriptional 
function of the Ala263Val mutant TRα1. By contrast, this 
aminoacid change is unlikely to have an eﬀ ect on TRα2 
function. Normal TRα2 does not bind T3,
20 is devoid of 
intrinsic transcriptional activity, and is a weak dominant-
negative inhibitor of TRα1 function,21,22 perhaps because 
it interacts poorly with retinoid X receptor and 
corepressors,22,23 making additional loss-of-function as a 
result of the Ala263Val mutation unlikely. Conversely, 
although blocking phosphorylation of aminoacids at the 
TRα2 carboxyterminus induces dominant-negative 
inhibitory function,24 the Ala263Val mutation is located 
outwith this domain.
Our patients had numerous skin tags and moles, which 
we have also noted in other patients with resistance to 
thyroid hormone caused by mutations in TRα1 
(appendix).9 Although present in the general population, 
the universal occurrence of this feature in people with 
defective TRα—even in childhood—suggests that it 
might be an additional characteristic of the disorder, 
although its absence would not exclude diagnosis. The 
enzyme DIO3 is present in human skin25 and its 
expression is regulated by TRα1,26 such that people with 
defective TRα might have diminished DIO3 activity. 
Topical inhibition of DIO3 activity enhances keratinocyte 
proliferation in mice25 and we speculate that cutaneous 
DIO3 deﬁ ciency in patients with defective TRα1 might 
mediate this phenotype. DIO3 deﬁ ciency or upregulation 
of hepatic DIO1 (as suggested by studies of TRα1 mutant 
mice12) might also mediate the low free thryoxine and 
high free T3 concentrations, low ratios of free 
thryoxine:free T3 and subnormal total reverse T3 
concentrations recorded in our patients.
Unlike previous reports of patients with highly 
deleterious TRα1 defects,7,8,10 high concentrations of T3 
reversed Ala263Val mutant TRα1 dysfunction and 
dominant-negative activity in vitro. T3 exposure restored 
subnormal expression of KLF9 in mutation-containing 
primary blood mononuclear cells, suggesting that 
dominant-negative inhibition by mutant TRα1 can also 
be overcome in vivo. We correlate these observations 
with improvement in some peripheral markers of thyroid 
hormone action (resting energy expenditure, creatine 
kinase) after thyroxine treatment; moreover, thyroid 
hormone treatment at physiological dose raised T3 
concentrations and suppressed TSH concentrations in 
patients 1 and 2, suggesting that the pituitary-thyroid axis 
is still sensitive to thyroid hormones in these patients.
Starting thyroxine treatment in childhood improved 
growth and development, and alleviated symptoms in 
adulthood without abnormally increasing concentrations 
of markers of bone turnover, as recorded previously.10 In 
transgenic mice harbouring a mutant TRα1 (arg384cys) 
with ten-fold reduced binding aﬃ  nity towards T3, 
increased con centrations of thyroid hormones can reverse 
neuro logical abnormalities.27 Neuro cognitive abnor-
malities might be less severe in these three patients 
because of early thyroid hormone treatment, but we 
cannot be certain of this possibility.
The identiﬁ cation of patients with equivalent defects in 
TRα1 and TRβ tempts the speculation that other patients 
with TRα1 mutations might exist. Roughly 125 diﬀ erent 
mutations in TRβ are known to cause resistance to thyroid 
hormone.4,5 Furthermore, maternal inheritance of the TRα 
mutation in this family, and paternal inheritance of the 
TRα mutation in another family,8 suggests that 
transmission of TRα mutations from parents to oﬀ spring 
may not be as impaired in people as in mice.12 With thyroid 
hormone con centrations being almost normal in patients 
with resistance to thyroid hormone caused by mutations 
in TRα, the clinical and biochemical characteristics of this 
family (together with features of previous cases) deﬁ ne a 
phenotypic signature for this syndrome (panel). This 
signature should enable early identiﬁ cation and treatment 
of other patients, which would be of particular importance 
should thyroxine treatment prove to be widely beneﬁ cial 
for this disorder.
Panel: Research in context
Systematic review
We searched PubMed with the terms “THRA” and “mutation” 
for studies published in English between 2000 and 2014. 
Previously reported cases7–10 of resistance to thyroid hormone 
caused by THRA mutations involve mutations that selectively 
disrupt thyroid hormone receptor (TR)α1 function, 
manifesting with typical features of hypothyroidism but 
paradoxically near-normal circulating thyroid hormone 
concentrations. A patient described in an abstract17 had some 
hypothyroid features and near-normal hormone 
concentrations, but also many dissimilar characteristics that 
may not be caused by the THRA defect. 
Interpretation
We describe the ﬁ rst patients with a mutation common to 
TRα1 and the variant TRα2 protein derived from the same 
gene. Their clinical (growth and developmental retardation, 
constipation, macrocephaly) and biochemical features 
(subnormal ratio of free thyroxine:free tri-iodothyronine [T3], 
low reverse T3) are similar to previous patients with resistance 
to thyroid hormone caused by mutation in TRα1, with no 
added phenotype attributable to the presence of mutant 
TRα2. T3 reverses mutant receptor dysfunction in vitro and 
thyroxine therapy alleviates hormone resistance in vivo; 
starting treatment with thyroxine in childhood might have 
ameliorated their clinical phenotype. Future identiﬁ cation of 
other patients, based on common characteristics of these and 
previous patients that now deﬁ ne the syndrome, will be of 
clinical importance if early thyroxine treatment proves to be 
widely beneﬁ cial.
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